Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)

Weiwei Lin; Fatemeh Mousavi; Benjamin C. Blum; Christian F. Heckendorf; Jarrod Moore; Noah Lampl; Mark McComb; Sergei Kotelnikov; Wenqing Yin; Nabil Rabhi; Matthew D. Layne; Dima Kozakov; Vipul C. Chitalia; Andrew Emili

doi:10.3389/fphar.2024.1376058

Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)

Weiwei Lin, Fatemeh Mousavi, Benjamin C. Blum, Christian F. Heckendorf, Jarrod Moore, Noah Lampl, Mark McComb, Sergei Kotelnikov, Wenqing Yin, Nabil Rabhi, Matthew D. Layne, Dima Kozakov, Vipul C. Chitalia, Andrew Emili

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the published article, there was an error in the Funding statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.” The correct Funding statement appears below. “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original language	English (US)
Article number	1376058
Journal	Frontiers in Pharmacology
Volume	15
DOIs	https://doi.org/10.3389/fphar.2024.1376058
State	Published - 2024
Externally published	Yes

Keywords

ESKD
integrated omics
metabolomics
nLC-MS/MS
proteomics

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.3389/fphar.2024.1376058

Cite this

Lin, W., Mousavi, F., Blum, B. C., Heckendorf, C. F., Moore, J., Lampl, N., McComb, M., Kotelnikov, S., Yin, W., Rabhi, N., Layne, M. D., Kozakov, D., Chitalia, V. C., & Emili, A. (2024). Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505). Frontiers in Pharmacology, 15, Article 1376058. https://doi.org/10.3389/fphar.2024.1376058

Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505). / Lin, Weiwei; Mousavi, Fatemeh; Blum, Benjamin C. et al.
In: Frontiers in Pharmacology, Vol. 15, 1376058, 2024.

Research output: Contribution to journal › Comment/debate › peer-review

Lin, W, Mousavi, F, Blum, BC, Heckendorf, CF, Moore, J, Lampl, N, McComb, M, Kotelnikov, S, Yin, W, Rabhi, N, Layne, MD, Kozakov, D, Chitalia, VC & Emili, A 2024, 'Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)', Frontiers in Pharmacology, vol. 15, 1376058. https://doi.org/10.3389/fphar.2024.1376058

@article{d80b5f284a1746a3af70c3b82122a35b,

title = "Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)",

abstract = "In the published article, there was an error in the Funding statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.” The correct Funding statement appears below. “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.",

keywords = "ESKD, integrated omics, metabolomics, nLC-MS/MS, proteomics",

author = "Weiwei Lin and Fatemeh Mousavi and Blum, {Benjamin C.} and Heckendorf, {Christian F.} and Jarrod Moore and Noah Lampl and Mark McComb and Sergei Kotelnikov and Wenqing Yin and Nabil Rabhi and Layne, {Matthew D.} and Dima Kozakov and Chitalia, {Vipul C.} and Andrew Emili",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 Lin, Mousavi, Blum, Heckendorf, Moore, Lampl, McComb, Kotelnikov, Yin, Rabhi, Layne, Kozakov, Chitalia and Emili.",

year = "2024",

doi = "10.3389/fphar.2024.1376058",

language = "English (US)",

volume = "15",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Corrigendum

T2 - Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)

AU - Lin, Weiwei

AU - Mousavi, Fatemeh

AU - Blum, Benjamin C.

AU - Heckendorf, Christian F.

AU - Moore, Jarrod

AU - Lampl, Noah

AU - McComb, Mark

AU - Kotelnikov, Sergei

AU - Yin, Wenqing

AU - Rabhi, Nabil

AU - Layne, Matthew D.

AU - Kozakov, Dima

AU - Chitalia, Vipul C.

AU - Emili, Andrew

PY - 2024

Y1 - 2024

N2 - In the published article, there was an error in the Funding statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.” The correct Funding statement appears below. “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

AB - In the published article, there was an error in the Funding statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.” The correct Funding statement appears below. “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

KW - ESKD

KW - integrated omics

KW - metabolomics

KW - nLC-MS/MS

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=85185521294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185521294&partnerID=8YFLogxK

U2 - 10.3389/fphar.2024.1376058

DO - 10.3389/fphar.2024.1376058

M3 - Comment/debate

AN - SCOPUS:85185521294

SN - 1663-9812

VL - 15

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 1376058

ER -

Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this